Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents

Profiling and comparison of two drug compendia

Chen May Wong, Yu Ko, Alexandre Chan

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

BACKGROUND: Use of oral anticancer agents is gaining wide acceptance in the treatment of cancer. However, patients receiving oral therapy are at high risk for drug-drug interactions (DDIs). OBJECTIVE: TO create a drug profile for each clinically significant DDI involving selected oral anticancer agents and evaluate the agreement between 2 commonly used DDI compendia: Drug Interaction Facts (DIF) 2008 and Micromedex DRUGDEX. METHODS: DDI profiles were developed based on primary and tertiary literature reviews. DIF 2008 and Micromedex DRUGDEX were compared to assess the consistency of listings, severity, and scientific evidence ratings of DDIs involving the oral anticancer agents that were selected. The Spearman correlation test was used to assess the correlation of the severity ratings between the 2 compendia. RESULTS: A total of 184 DDIs were identified. A DDI profile was created for 40 of these that met the predetermined criteria for clinically significant interactions. The comparative assessment showed inconsistency in DDI listings (15.2% of those identified were listed in DIF only and 46.7% were listed in Micromedex only), severity ratings (Spearman correlation coefficient 0.49), and scientific evidence ratings (disagreement 25.8%). CONCLUSIONS: The discrepancies in DDI listing and rating systems between the compendia evaluated here reflect the need for more studies to standardize the definitions and classifications of DDIs.

Original languageEnglish
Pages (from-to)1737-1748
Number of pages12
JournalAnnals of Pharmacotherapy
Volume42
Issue number12
DOIs
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Drug Interactions
Antineoplastic Agents
Pharmaceutical Preparations

Keywords

  • Drug compendia
  • Drug information
  • Drug-drug interactions

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents : Profiling and comparison of two drug compendia. / Wong, Chen May; Ko, Yu; Chan, Alexandre.

In: Annals of Pharmacotherapy, Vol. 42, No. 12, 2008, p. 1737-1748.

Research output: Contribution to journalArticle

@article{3e99fa08e1984704a13f4431eb5a971d,
title = "Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: Profiling and comparison of two drug compendia",
abstract = "BACKGROUND: Use of oral anticancer agents is gaining wide acceptance in the treatment of cancer. However, patients receiving oral therapy are at high risk for drug-drug interactions (DDIs). OBJECTIVE: TO create a drug profile for each clinically significant DDI involving selected oral anticancer agents and evaluate the agreement between 2 commonly used DDI compendia: Drug Interaction Facts (DIF) 2008 and Micromedex DRUGDEX. METHODS: DDI profiles were developed based on primary and tertiary literature reviews. DIF 2008 and Micromedex DRUGDEX were compared to assess the consistency of listings, severity, and scientific evidence ratings of DDIs involving the oral anticancer agents that were selected. The Spearman correlation test was used to assess the correlation of the severity ratings between the 2 compendia. RESULTS: A total of 184 DDIs were identified. A DDI profile was created for 40 of these that met the predetermined criteria for clinically significant interactions. The comparative assessment showed inconsistency in DDI listings (15.2{\%} of those identified were listed in DIF only and 46.7{\%} were listed in Micromedex only), severity ratings (Spearman correlation coefficient 0.49), and scientific evidence ratings (disagreement 25.8{\%}). CONCLUSIONS: The discrepancies in DDI listing and rating systems between the compendia evaluated here reflect the need for more studies to standardize the definitions and classifications of DDIs.",
keywords = "Drug compendia, Drug information, Drug-drug interactions",
author = "Wong, {Chen May} and Yu Ko and Alexandre Chan",
year = "2008",
doi = "10.1345/aph.1L255",
language = "English",
volume = "42",
pages = "1737--1748",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "12",

}

TY - JOUR

T1 - Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents

T2 - Profiling and comparison of two drug compendia

AU - Wong, Chen May

AU - Ko, Yu

AU - Chan, Alexandre

PY - 2008

Y1 - 2008

N2 - BACKGROUND: Use of oral anticancer agents is gaining wide acceptance in the treatment of cancer. However, patients receiving oral therapy are at high risk for drug-drug interactions (DDIs). OBJECTIVE: TO create a drug profile for each clinically significant DDI involving selected oral anticancer agents and evaluate the agreement between 2 commonly used DDI compendia: Drug Interaction Facts (DIF) 2008 and Micromedex DRUGDEX. METHODS: DDI profiles were developed based on primary and tertiary literature reviews. DIF 2008 and Micromedex DRUGDEX were compared to assess the consistency of listings, severity, and scientific evidence ratings of DDIs involving the oral anticancer agents that were selected. The Spearman correlation test was used to assess the correlation of the severity ratings between the 2 compendia. RESULTS: A total of 184 DDIs were identified. A DDI profile was created for 40 of these that met the predetermined criteria for clinically significant interactions. The comparative assessment showed inconsistency in DDI listings (15.2% of those identified were listed in DIF only and 46.7% were listed in Micromedex only), severity ratings (Spearman correlation coefficient 0.49), and scientific evidence ratings (disagreement 25.8%). CONCLUSIONS: The discrepancies in DDI listing and rating systems between the compendia evaluated here reflect the need for more studies to standardize the definitions and classifications of DDIs.

AB - BACKGROUND: Use of oral anticancer agents is gaining wide acceptance in the treatment of cancer. However, patients receiving oral therapy are at high risk for drug-drug interactions (DDIs). OBJECTIVE: TO create a drug profile for each clinically significant DDI involving selected oral anticancer agents and evaluate the agreement between 2 commonly used DDI compendia: Drug Interaction Facts (DIF) 2008 and Micromedex DRUGDEX. METHODS: DDI profiles were developed based on primary and tertiary literature reviews. DIF 2008 and Micromedex DRUGDEX were compared to assess the consistency of listings, severity, and scientific evidence ratings of DDIs involving the oral anticancer agents that were selected. The Spearman correlation test was used to assess the correlation of the severity ratings between the 2 compendia. RESULTS: A total of 184 DDIs were identified. A DDI profile was created for 40 of these that met the predetermined criteria for clinically significant interactions. The comparative assessment showed inconsistency in DDI listings (15.2% of those identified were listed in DIF only and 46.7% were listed in Micromedex only), severity ratings (Spearman correlation coefficient 0.49), and scientific evidence ratings (disagreement 25.8%). CONCLUSIONS: The discrepancies in DDI listing and rating systems between the compendia evaluated here reflect the need for more studies to standardize the definitions and classifications of DDIs.

KW - Drug compendia

KW - Drug information

KW - Drug-drug interactions

UR - http://www.scopus.com/inward/record.url?scp=84984534151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984534151&partnerID=8YFLogxK

U2 - 10.1345/aph.1L255

DO - 10.1345/aph.1L255

M3 - Article

VL - 42

SP - 1737

EP - 1748

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 12

ER -